Skip to main content

Letters to opioid manufacturers


Excerpt: “We are continuing our work investigating the causes and effects of the opioid epidemic. Last Congress, the Committee on Energy and Commerce began bipartisan investigations into fentanyl, opioid manufacturing, opioid distribution, and the substance use disorder treatment industry,” the leaders write in the letters. “We write today to reactivate the investigation started on August 2, 2018, that examined potential breakdowns in the controlled substances supply chain, which may have contributed to the nation’s opioid epidemic, and the role of certain opioid manufacturers in such potential breakdowns.”  

Click here to read the letter to Insys Therapeutics

Click here to read the letter Mallinckrodt Pharmaceuticals

Click here to read the letter to Purdue Pharma